Skip to main content

Gerald G. Krueger, MD

Languages spoken: English

Academic Information

Departments: Dermatology - Professor

Academic Office Information

gerald.krueger@hsc.utah.edu

Board Certification

  • American Board of Dermatology (Dermatology)

Research Interests

  • Psoriasis
Gerald Krueger, MD is an expert in the diagnosis and treatment of psoriasis and hair loss. He is board certified in dermatology. Involved in over 100 clinical trials on psoriasis since being recruited to the University of Utah in 1972. In 2001 Dr. Krueger and Dr Callis Duffin started the Utah Psoriasis Initiative with the goal of creating a registry of patients with psoriasis. This registry contains medical and genetic information of the over 1400 participants that have been enrolled. The information is being collected to identify genes that cause different levels of risk for psoriasis and other diseases.

Education History

Residency University of Colorado
Dermatology
Resident
Internship Fitzsimons Army Medical Center
Intern
Professional Medical Loma Linda University
M.D.
Undergraduate Union College
Chemistry
B.A.

Selected Publications

  1. Harris KM, Smilek DE, Byron M, Lim N, Barry WT, McNamara J, Garcet S, Konrad RJ, Stengelin M, Bathala P, Korman NJ, Feldman SR, Boh EE, Barber K, Laumann AE, Helfrich YR, Krueger GG, Sofen H, Bissonnette R, Krueger JG (2021). Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis: The PAUSE Randomized Clinical Trial. JAMA Dermatol (157(11), pp. 1306-1315). United States.
  2. Papp KA, Lebwohl MG, Kircik LH, Pariser DM, Strober B, Krueger GG, Berk DR, Navale L, Higham RC (2021). The Proposed PASI-HD Provides More Precise Assessment of Plaque Psoriasis Severity in Anatomical Regions with a Low Area Score. [Letter to the editor]. Dermatol Ther (Heidelb), 11(4), 1079-1083.
  3. Belman S, Walsh JA, Carroll C, Milliken M, Haaland B, Callis Duffin K, Krueger GG, Feng BJ (2021). Psoriasis characteristics for the early detection of psoriatic arthritis. J Rheumatol, 48(10), 1559-1565.
  4. Menter A, Krueger GG, Paek SY, Kivelevitch D, Adamopoulos IE, Langley RG (2021). Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatol Ther (Heidelb), 11(2), 385-400.
  5. Armstrong AW, Blauvelt A, Crowley JJ, Gordon KB, Krueger GG, Krueger JG, Sobell JM, Strober BE, Srivastava B, Menter A (2020). Defining drug-free remission of skin disease in patients with plaque psoriasis. [Letter to the editor]. Br J Dermatol, 182(6), 1484-1487.
  6. Coates LC, FitzGerald O, Mease PJ, Gladman DD, Strand V, Goel N, Campbell I, Krueger G, McHugh NJ, Helliwell PS (2014). Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11. J Rheumatol, 41(4), 782-91.
  7. Zhang J, Xu X, Rao NV, Argyle B, McCoard L, Rusho WJ, Kennedy TP, Prestwich GD, Krueger G (2011). Novel sulfated polysaccharides disrupt cathelicidins, inhibit RAGE and reduce cutaneous inflammation in a mouse model of rosacea. PLoS One, 6(2), e16658.
  8. Soltani-Arabshahi R, Wong B, Feng BJ, Goldgar DE, Duffin KC, Krueger GG (2010). Obesity in early adulthood as a risk factor for psoriatic arthritis. Arch Dermatol, 146(7), 721-6.
  9. Duffin KC, Woodcock J, Krueger GG (2010). Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association. Dermatol Ther, 23(2), 101-13.
  10. Rakkhit T, Panko JM, Christensen TE, Wong B, Nelson T, Papenfuss J, Hansen CB, Callis-Duffin K, Krueger GG (2009). Plaque thickness and morphology in psoriasis vulgaris associated with therapeutic response. Br J Dermatol, 160(5), 1083-9.
  11. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, Ruether A, Schreiber S, Weichenthal M, Gladman D, Rahman P, Schrodi SJ, Prahalad S, Guthery SL, Fischer J, Liao W, Kwok PY, Menter A, Lathrop GM, Wise CA, Begovich AB, Voorhees JJ, Elder JT, Krueger GG, Bowcock AM, Abecasis GR (2009). Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet, 41(2), 199-204.
  12. Krueger GG, Langley RG, Leonardi C, Yeilding N, Guzzo C, Wang Y, Dooley LT, Lebwohl M, CNTO 1275 Psoriasis Study Group (2007). A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med, 356(6), 580-92.
  13. Cargill M, Schrodi SJ, Chang M, Garcia VE, Brandon R, Callis KP, Matsunami N, Ardlie KG, Civello D, Catanese JJ, Leong DU, Panko JM, McAllister LB, Hansen CB, Papenfuss J, Prescott SM, White TJ, Leppert MF, Krueger GG, Begovich AB (2007). A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet, 80(2), 273-90.
  14. Christensen TE, Callis KP, Papenfuss J, Hoffman MS, Hansen CB, Wong B, Panko JM, Krueger GG (2006). Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes. J Invest Dermatol, 126(11), 2397-403.
  15. Herron MD, Hinckley M, Hoffman MS, Papenfuss J, Hansen CB, Callis KP, Krueger GG (2005). Impact of obesity and smoking on psoriasis presentation and management. Arch Dermatol, 141(12), 1527-34.
  16. Krueger G, Ellis CN (2005). Psoriasis--recent advances in understanding its pathogenesis and treatment. J Am Acad Dermatol, 53(1 Suppl 1), S94-100.
  17. Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG (2004). A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol, 50(6), 859-66.
  18. Krueger G, Callis K (2004). Potential of tumor necrosis factor inhibitors in psoriasis and psoriatic arthritis. Arch Dermatol, 140(2), 218-25.
  19. Ellis CN, Krueger GG (2001). Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med, 345(4), 248-55.
  20. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Weinstein GD, Barton TL, Rolstad T, Day RM (2000). Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol, 43(2 Pt 1), 281-5.
  21. Petersen MJ, Kaplan J, Jorgensen CM, Schmidt LA, Li L, Morgan JR, Kwan MK, Krueger GG (1995). Sustained production of human transferrin by transduced fibroblasts implanted into athymic mice: a model for somatic gene therapy. J Invest Dermatol, 104(2), 171-6.
  22. Krueger GG Assignee: University of Utah Research Foundation (1987). "Methods of Testing the Reaction of Various Substances on Living Human Skin" This patent describes what we have come to call the Rat Human Skin sandwich Flap (RHSSF). U.S. Patent No. 4,677,968. Washington, D.C.:U.S. Patent and Trademark Office.
  23. Wojciechowski Z, Pershing LK, Huether S, Leonard L, Burton SA, Higuchi WI, Krueger GG (1987). An experimental skin sandwich flap on an independent vascular supply for the study of percutaneous absorption. J Invest Dermatol, 88(4), 439-46.
  24. Gilhar A, Krueger GG (1987). Hair growth in scalp grafts from patients with alopecia areata and alopecia universalis grafted onto nude mice. Arch Dermatol, 123(1), 44-50.
  25. Krueger GG, Chambers DA, Shelby J (1981). Involved and uninvolved skin from psoriatic subjects: are they equally diseased? Assessment by skin transplanted to congenitally athymic (nude) mice. J Clin Invest, 68(6), 1548-57.